Vitamin E Dosing in AREDS2 Supplementation for Age-Related Macular Degeneration
For an older adult with age-related macular degeneration taking an AREDS2 supplement, the recommended daily dose of vitamin E (α-tocopherol) is 400 IU (approximately 268 mg of natural d-α-tocopherol). 1
Standard AREDS2 Formulation
The AREDS2 formulation maintains the original AREDS vitamin E dose at 400 IU daily, which has been validated in large-scale randomized controlled trials to reduce progression to advanced AMD by approximately 25% in patients with intermediate AMD or advanced AMD in one eye. 1, 2
The 400 IU dose of vitamin E is combined with 500 mg vitamin C, 80 mg zinc (or 25 mg in modified formulations), 2 mg copper, 10 mg lutein, and 2 mg zeaxanthin in the complete AREDS2 supplement. 3, 2
This vitamin E dosage was established in the original AREDS trial and carried forward into AREDS2, where all participants were offered the AREDS formulation as a baseline supplement. 3, 2
Evidence Supporting This Dose
The 400 IU vitamin E dose demonstrated efficacy in slowing AMD progression in the landmark AREDS trial, with people taking the antioxidant formulation (including 400 IU vitamin E) showing reduced odds of progressing to late AMD (OR 0.72,95% CI 0.58 to 0.90). 2
For patients with intermediate AMD at higher risk of progression, this translates to approximately 78 fewer cases of progression to late AMD per 1000 people taking the supplements over 5 years. 1
The formulation also reduced risk of neovascular AMD (OR 0.62,95% CI 0.47 to 0.82) and vision loss of 3 or more lines (OR 0.77,95% CI 0.62 to 0.96). 2
Safety Considerations at This Dose
The 400 IU daily dose of vitamin E is well below safety thresholds and has been extensively studied without major adverse effects. 4
Clinical evidence indicates that vitamin E supplements up to 1600 IU daily (1073 mg d-α-tocopherol) appear safe for most adults, making the 400 IU AREDS2 dose conservative. 4
The primary adverse effects of AREDS2 supplementation are gastrointestinal discomfort, with no major safety concerns identified in the trial data. 1
Long-term studies confirm no increased risk of cardiovascular events or mortality with vitamin E supplementation at doses ≤400 IU daily. 4
Important Clinical Caveats
Do not modify the vitamin E dose independently—the AREDS2 formulation works as a complete package, and the 400 IU vitamin E dose is part of the validated combination that demonstrated clinical benefit. 2
Patients must have either bilateral intermediate AMD (large drusen ≥125 µm with pigmentary changes) or advanced AMD in one eye to meet criteria for AREDS2 supplementation. 1
Smoking cessation is mandatory, as smoking is a major dose-dependent risk factor for AMD progression that can negate supplement benefits. 1
The 400 IU dose applies regardless of dietary vitamin E intake, as the AREDS trials used this fixed dose without adjustment for baseline dietary consumption. 3, 2